• Precigen recently announced it will release its first quarter 2026 financial results and business updates on May 13, 2026, alongside a conference call, with management indicating that PAPZIMEOS revenue for the period is expected to exceed US$18,000,000.
• This update highlights how the company’s shift to a commercial rare disease platform, anchored by PAPZIMEOS for recurrent respiratory papillomatosis, is starting to show through in early revenue traction despite ongoing reimbursement frictions.
• We’ll now examine how the anticipated US$18,000,000 plus in PAPZIMEOS quarterly revenue may reshape Precigen’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Precigen Investment Narrative Recap

To own Precigen, you have to believe PAPZIMEOS can support a sustainable commercial rare disease business while the company manages heavy fixed costs and past funding concerns. The Q1 2026 update, with PAPZIMEOS revenue expected above US$18,000,000, directly affects the key near term catalyst of validating demand, while also starting to test whether current uptake can eventually cover commercial and manufacturing spend. The biggest risk around reimbursement and pricing remains, but early traction suggests this news is not immaterial.

The most relevant recent announcement here is the January 2026 expert consensus paper that endorsed PAPZIMEOS as the new first line standard of care for adults with RRP. Combined with the expectation of more than US$18,000,000 in Q1 PAPZIMEOS sales, this professional endorsement is an important context for investors watching whether physician enthusiasm can translate into sustained treatment growth despite reimbursement frictions and the company’s reliance on a single approved indication for now.

Yet behind the early revenue traction, investors should be aware of the ongoing risk that reimbursement hurdles and higher than expected gross to net discounts could...

Precigen's narrative projects $299.5 million revenue and $118.4 million earnings by 2028. This requires 262.1% yearly revenue growth and an earnings increase of about $544 million from -$425.9 million today.

Uncover how Precigen's forecasts yield a $8.50 fair value, a 105% upside to its current price.

Exploring Other Perspectives

Ten fair value estimates from the Simply Wall St Community span roughly US$0.50 to US$42 per share, showing how far apart individual views can be. Against that backdrop, the focus on whether PAPZIMEOS revenue can scale fast enough to support Precigen’s commercial and manufacturing cost base gives you a clear lens to compare these differing expectations about the company’s future performance.

Explore 10 other fair value estimates on Precigen - why the stock might be worth over 10x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Precigen research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Precigen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Precigen's overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.